DUBLIN--(BUSINESS WIRE)--The "West Syndrome - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
West Syndrome - Epidemiology Forecast to 2030 delivers an in-depth understanding of the disease, historical and forecasted West Syndrome epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
West Syndrome Epidemiology Perspective
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalent Population of West Syndrome, Diagnosed Prevalent Population of west Syndrome and Gender-specific Diagnosed Prevalence of West Syndrome in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.
West Syndrome Detailed Epidemiology Segmentation
- The total diagnosed prevalent population of West Syndrome in the 7 major markets was found to be 8,057 in 2017.
- In the United States, the diagnosed prevalent cases of West Syndrome was found to be 3,999 in 2017.
- The publisher has also analyzed gender-specific data for West Syndrome, which clearly suggests that it is more prevalent among males than females. It was found that in the United States the number of cases of West Syndrome in males and females were 2,399 and 1,600 respectively in 2017.
- In the EU5 countries the diagnosed prevalence of West Syndrome was found to be maximum in France with 737 cases, followed by the United Kingdom with 684 cases in 2017. While, the least number of cases were found in Spain, with 445 cases in 2017.
- In Japan, the diagnosed prevalence of West Syndrome was found to be 1,090 in 2017.
Report Highlights
- Eleven Year Forecast of West Syndrome
- 7MM Coverage
- Diagnosed Prevalent Population of West Syndrome
- Report also covers Gender-specific diagnosed prevalence of West Syndrome, which clearly remarks a male preponderance and this finding maintains the hypothesis that male sex is a risk factor.
- Expected launch of a potential therapies, Cannabidiol (CBD) oral solution (INSYS Therapeutics) and Epidiolex (GW Pharmaceuticals), may increase the market size in the coming years, assisted by an increase in diagnosed prevalent population of West Syndrome.
Key Questions Answered
- What is the disease risk, burden and unmet needs of West Syndrome?
- What is the historical West Syndrome patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
- What would be the forecasted patient pool of West Syndrome at the 7MM level?
- What will be the growth opportunities across the 7MM with respect to the patient population pertaining to West Syndrome?
- Out of the above-mentioned countries, which country would have the highest prevalent population of West Syndrome during the forecast period (2020-2030)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?
Key Topics Covered:
1 Key Insights
2 West Syndrome Overview at a Glance
3 Executive Summary of West Syndrome
4 West Syndrome: Disease Background and Overview
4.1 Introduction
4.2 Metabolic etiologies in West syndrome
4.3 Etiology-specific Subtypes of West syndrome
4.4 Causes and Risk Factors
4.5 Clinical Manifestations
4.6 Symptoms
4.7 Pathophysiology
4.8 Diagnosis
4.9 Differential Diagnosis
4.10 Prognosis
5 Diagnostic Algorithm for West Syndrome
6 Clinical Algorithm for Epileptic Spasms (Infantile Spasms) By Texas Children's Hospital
7 Epidemiology and Patient Population
7.1 Key Findings
7.2 7MM Total Prevalent Population of West Syndrome
7.3 7MM Total Diagnosed Prevalent Population of West Syndrome
8 Country-wise Epidemiology of West Syndrome
8.1 Assumptions and Rationale: 7MM Countries
8.2 United States
8.2.1 Assumptions and Rationale
8.2.2 Total Prevalent Population of West Syndrome in the United States
8.2.3 Total Diagnosed Prevalent Population of West Syndrome in the United States
8.2.4 Gender-specific Diagnosed Prevalent Population of West Syndrome in the United States
8.3 EU5 Countries
8.3.1 Assumptions and Rationale
8.4 Germany
8.5 France
8.6 Italy
8.7 Spain
8.8 United Kingdom
8.9 Japan
8.9.1 Assumptions and Rationale
8.9.2 Total Prevalent Population of West Syndrome in Japan
8.9.3 Total Diagnosed Prevalent Population of West Syndrome in Japan
8.9.4 Gender-specific Diagnosed Prevalent Population of West Syndrome in Japan
9 Appendix
9.1 Bibliography
9.2 Report Methodology
10 Analyst Capabilities
For more information about this report visit https://www.researchandmarkets.com/r/6z3eca
